New Malaria Vaccine Administered to Children in Ivory Coast
Children in Ivory Coast have received the first doses of a new malaria vaccine, the R21 vaccine, developed by the Jenner Institute at the University of Oxford and the Serum Institute of India. With high efficacy rates and affordability at less than $4 per dose, this vaccine has the potential to prevent up to 500,000 child deaths annually. The vaccination campaign aims to significantly reduce malaria-related deaths, with other countries like Ghana, Nigeria, Burkina Faso, and the Central African Republic also authorizing its use.
Uganda to Switch to New Malaria Vaccine for Children Under Five
Uganda is set to abandon the use of the first malaria vaccine, RTS,S (Mosquirix), in favor of the recently approved R21/Matrix-M vaccine for the immunization of children under five years old. The decision comes after the Health Ministry Division of Malaria Control revealed the country’s plan to initiate malaria vaccinations for young children starting in October. Learn more about Uganda’s switch to the R21/Matrix-M vaccine and its implications for combating malaria in the region.
Can a New Vaccine Change the Course of Tuberculosis?
Learn about the ongoing battle against tuberculosis (TB) in 2024 and the potential impact of new vaccines on this deadly disease. Despite existing preventive measures and treatments, TB continues to afflict millions globally, with over 10 million cases and 1.3 million deaths in 2022. Explore how novel TB vaccines targeting adolescents and adults offer hope for improved efficacy, marking a significant shift in the fight against this historic health threat.